• Journal Article

Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States

Citation

Nabhan, C., Zhou, X., Day, B. M., Dawson, K., Zelenetz, A. D., Friedberg, J. W., ... Flowers, C. R. (2016). Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. American Journal of Hematology, 91(8), 770-775. DOI: 10.1002/ajh.24401

Abstract

We aimed to comprehensively study sex differences in disease and patients' characteristics, treatment and outcomes in patients with follicular lymphoma (FL) in the United States (USA) utilizing the National LymphoCare Study registry (2004-2014). Among evaluable males (n=1277) and females (n=1375) with FL, females less commonly received anthracyclines and were more likely to receive rituximab monotherapy. Overall response rates were comparable between sex groups. With a median follow-up of 8.1 years, male sex emerged as an adverse factor for PFS (HR, 0.84, 95% CI, 0.72-0.97). Lymphoma-related mortality (HR, 0.46; 0.23-0.93) and overall survival (HR, 0.63; 0.41-0.97) favored females aged